Advanced Search
Search Results
6557 total results found
15.22 Presentations and management of liver diseas
15.22 Presentations and management of liver disease 3049
15.22.1 Investigation and management of jaundice 3
15.22.1 Investigation and management of jaundice 3049 CONTENTS 15.22.1 Investigation and management of jaundice 3049 Jane Collier 15.22.2 Cirrhosis and ascites 3058 Javier Fernández and Vicente Arroyo 15.22.3 Portal hypertension and variceal bleeding 306...
15.22.2 Cirrhosis and ascites 3058
15.22.2 Cirrhosis and ascites 3058 section 15 Gastroenterological disorders 3058 15.22.2 Cirrhosis and ascites Javier Fernández and Vicente Arroyo ESSENTIALS Ascites is the accumulation of fluid in the peritoneal cavity and the most common complication of ci...
15.22.3 Portal hypertension and variceal bleeding
15.22.3 Portal hypertension and variceal bleeding 3068 section 15 Gastroenterological disorders 3068 Fernández J, et al. (2007). Primary prophylaxis of spontaneous bac- terial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroe...
15.22.4 Hepatic encephalopathy 3080
15.22.4 Hepatic encephalopathy 3080 section 15 Gastroenterological disorders 3080 Fagundes C, Ginès P (2012). Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis, 59, 874–85. Ferguson JW, Tripathi D, Hayes PC ...
15.22.5 Liver failure 3089
15.22.5 Liver failure 3089 15.22.5 Liver failure 3089 investigate novel sensitive and specific biomarkers, further validate existing investigative tools, and develop clear diagnostic algorithms. With the growing recognition of the importance of systemic in- f...
15.22.6 Liver transplantation 3100
15.22.6 Liver transplantation 3100 section 15 Gastroenterological disorders 3100 Other approaches to further improve prognostic criteria include sequential assessment of liver volumes by CT. This is a new tool to assess liver collapse and thus infer hepatocel...
15.23 Hepatitis and autoimmune liver disease 3108
15.23 Hepatitis and autoimmune liver disease 3108
15.23.1 Hepatitis A to E 3108
15.23.1 Hepatitis A to E 3108 CONTENTS 15.23.1 Hepatitis A to E 3108 Graeme J.M. Alexander and Kate Nash 15.23.2 Autoimmune hepatitis 3119 G.J. Webb and Gideon M. Hirschfield 15.23.3 Primary biliary cholangitis 3127 Jessica K. Dyson and David E.J. Jones ...
15.23.2 Autoimmune hepatitis 3119
15.23.2 Autoimmune hepatitis 3119 15.23.2 Autoimmune hepatitis 3119 level and decreased necroinflammation on liver biopsy. Some pa- tients may clear HDV transiently, although HBsAg often persists and most patients experience virological relapse of HDV when th...
15.23.3 Primary biliary cholangitis 3127
15.23.3 Primary biliary cholangitis 3127 15.23.3 Primary biliary cholangitis 3127 Acknowledgements Prof Stefan Hübscher, Pathology, University Hospitals Birmingham, and Dr Abid Karim, Clinical Immunology, University Hospitals Birmingham, United Kingdom. FURTH...
15.23.4 Primary sclerosing cholangitis 3135
15.23.4 Primary sclerosing cholangitis 3135 15.23.4 Primary sclerosing cholangitis 3135 meet the minimal listing criteria (United Kingdom Model for End- Stage Liver Disease score of 49 or greater) based on a combination of markers of disease severity includi...
15.24 Other liver diseases 3142
15.24 Other liver diseases 3142
15.24.1 Alcoholic liver disease 3142
15.24.1 Alcoholic liver disease 3142 CONTENTS 15.24.1 Alcoholic liver disease 3142 Ewan Forrest 15.24.2 Nonalcoholic fatty liver disease 3147 Quentin M. Anstee and Christopher P. Day 15.24.3 Drug-induced liver disease 3155 Guruprasad P. Aithal 15.24.4 ...
15.24.2 Nonalcoholic fatty liver disease 3147
15.24.2 Nonalcoholic fatty liver disease 3147 15.24.2 Nonalcoholic fatty liver disease 3147 related to the stage of disease, as assessed by standard chronic liver disease scores such as the MELD score or the Child–Pugh score. The prognosis is improved by sus...
15.24.3 Drug- induced liver disease 3155
15.24.3 Drug- induced liver disease 3155 15.24.3 Drug-induced liver disease 3155 Therapy Gawrieh S, Chalasani N (2015). Pharmacotherapy for non-alcoholic fatty liver disease. Semin Liver Dis, 35, 338–48. Lombardi R, et al. (2017). Pharmacological intervent...
15.24.4 Vascular disorders of the liver 3166
15.24.4 Vascular disorders of the liver 3166 section 15 Gastroenterological disorders 3166 Padda MS, et al. (2011). Drug-induced cholestasis. Hepatology, 53, 1377–87. Ramappa V, Aithal GP (2013). Hepatotoxicity related to anti- tuberculosis drugs: mechan...
15.24.5 The liver in systemic disease 3169
15.24.5 The liver in systemic disease 3169 15.24.5 The liver in systemic disease 3169 with pain, sometimes in the back and rarely after cholecystectomy with jaundice and biliary obstruction. Spontaneous rupture has been associated with haemobilia and is a maj...